These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 17036536)

  • 1. [ASCO 2006. Exemestane: a new drug for the adjuvant therapy of breast cancer].
    Perrone F
    Tumori; 2006; 92(4):suppl 1-9. PubMed ID: 17036536
    [No Abstract]   [Full Text] [Related]  

  • 2. Switch to exemestane effective in early breast cancer.
    Gourd E
    Lancet Oncol; 2017 Jun; 18(6):e308. PubMed ID: 28506558
    [No Abstract]   [Full Text] [Related]  

  • 3. Exemestane in postmenopausal women with early or advanced breast cancer: a review.
    Bertelli G; Gangadhara S
    Expert Opin Pharmacother; 2010 Aug; 11(11):1933-42. PubMed ID: 20569090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exemestane: a milestone against breast cancer.
    Shetty YC; Chakkarwar PN; Acharya SS; Rajadhyaksha VD
    J Postgrad Med; 2007; 53(2):135-8. PubMed ID: 17495383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer.
    Şendur MA; Aksoy S; Akıncı MB; Ozdemir N; Dede DŞ; Altundag K; Zengin N; Yalçın B
    Future Oncol; 2015; 11(6):905-7. PubMed ID: 25760972
    [No Abstract]   [Full Text] [Related]  

  • 6. Experience with exemestane in the treatment of early and advanced breast cancer.
    Lønning PE; Geisler J
    Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):987-97. PubMed ID: 18624685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
    Freedman OC; Verma S; Clemons MJ
    Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of exemestane in the Intergroup Exemestane Study.
    Coombes RC; Bliss JM; Hall E
    J Clin Oncol; 2005 May; 23(13):3171-2. PubMed ID: 15860896
    [No Abstract]   [Full Text] [Related]  

  • 10. Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study.
    Bliss JM; Kilburn LS; Coleman RE; Forbes JF; Coates AS; Jones SE; Jassem J; Delozier T; Andersen J; Paridaens R; van de Velde CJ; Lønning PE; Morden J; Reise J; Cisar L; Menschik T; Coombes RC
    J Clin Oncol; 2012 Mar; 30(7):709-17. PubMed ID: 22042946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National Cancer Institute of Canada Clinical Trials Group MAP.3 Trial: evaluation of exemestane to prevent breast cancer in postmenopausal women.
    Goss PE; Richardson H; Chlebowski R; Johnston D; Sarto GE; Maunsell E; Ingle JN; Alés-Martinez JE
    Clin Breast Cancer; 2007 Dec; 7(11):895-900. PubMed ID: 18269782
    [No Abstract]   [Full Text] [Related]  

  • 12. [New results of endocrine therapy of breast cancer (the role of Aromasin)].
    Semiglazov VF; Semiglazov VV; Klemtsel' AA; Barash NIu; Zhil'tsova EK; Bozhok AA; Mel'nikova OA; Paltuev RM; Dashian GA; Petrovskiĭ SG; Ivanov VG; Tonuzov EE; Berstein LM
    Vopr Onkol; 2004; 50(6):729-36. PubMed ID: 15755074
    [No Abstract]   [Full Text] [Related]  

  • 13. Exemestane-induced radiation recall dermatitis and morbilliform rash.
    Marchand A; Georgin-Mège M; Cellier P; Martin L; Avenel-Audran M; Le Corre Y
    J Dermatol; 2016 May; 43(5):575-6. PubMed ID: 26813265
    [No Abstract]   [Full Text] [Related]  

  • 14. Aromatase inhibitors and bone loss: risks in perspective.
    Shapiro CL
    J Clin Oncol; 2005 Aug; 23(22):4847-9. PubMed ID: 15983395
    [No Abstract]   [Full Text] [Related]  

  • 15. Adjuvant aromatase inhibitor therapy for early breast cancer: A review of the most recent data.
    Grana G
    J Surg Oncol; 2006 Jun; 93(7):585-92. PubMed ID: 16705732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmenopausal women with DCIS post-mastectomy: a potential role for aromatase inhibitors.
    Chlebowski RT; Col N
    Breast J; 2012; 18(4):299-302. PubMed ID: 22681627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolving role of exemestane in the management of breast cancer.
    Bundred N
    Br J Hosp Med (Lond); 2006 Aug; 67(8):427-30. PubMed ID: 16918105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?
    Hutchinson L
    Nat Clin Pract Oncol; 2004 Nov; 1(1):24-5. PubMed ID: 16264795
    [No Abstract]   [Full Text] [Related]  

  • 19. Aromatase inhibitors in the breast cancer clinic: focus on exemestane.
    Van Asten K; Neven P; Lintermans A; Wildiers H; Paridaens R
    Endocr Relat Cancer; 2014 Feb; 21(1):R31-49. PubMed ID: 24434719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exemestane following tamoxifen in postmenopausal women with primary breast cancer.
    Mouridsen HT
    J Clin Oncol; 2004 Sep; 22(18):3833-4. PubMed ID: 15365083
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.